Catalyst Pharmaceuticals, a leader in the commercial-stage biopharmaceutical industry, is directing their focus towards developing and marketing therapies for rare neuromuscular and neurological diseases in the United States. The company’s flagship offerings, Firdapse and Ruzurgi, are amifampridine phosphate tablets for patients with lambert-eaton myasthenic syndrome (LEMS) and pediatric LEMS patients, respectively. Catalyst is also developing Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. The company holds license agreements with BioMarin Pharmaceutical Inc. and a collaboration and license agreement with Endo Ventures Limited to develop and sell generic Sabril tablets. Catalyst Pharmaceuticals, which was established in 2002, is headquartered in Coral Gables, Florida.